ZA200906739B - Use of HDAC inhibitors for the treatment of gastrointestinal cancers - Google Patents

Use of HDAC inhibitors for the treatment of gastrointestinal cancers

Info

Publication number
ZA200906739B
ZA200906739B ZA200906739A ZA200906739A ZA200906739B ZA 200906739 B ZA200906739 B ZA 200906739B ZA 200906739 A ZA200906739 A ZA 200906739A ZA 200906739 A ZA200906739 A ZA 200906739A ZA 200906739 B ZA200906739 B ZA 200906739B
Authority
ZA
South Africa
Prior art keywords
treatment
hdac inhibitors
gastrointestinal cancers
cancers
gastrointestinal
Prior art date
Application number
ZA200906739A
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200906739(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200906739B publication Critical patent/ZA200906739B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200906739A 2007-05-04 2009-09-28 Use of HDAC inhibitors for the treatment of gastrointestinal cancers ZA200906739B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
ZA200906739B true ZA200906739B (en) 2010-06-30

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200906739A ZA200906739B (en) 2007-05-04 2009-09-28 Use of HDAC inhibitors for the treatment of gastrointestinal cancers

Country Status (16)

Country Link
EP (1) EP2142190A1 (en)
JP (1) JP2010526149A (en)
KR (1) KR20100016171A (en)
CN (1) CN101674825A (en)
AU (1) AU2008247603A1 (en)
BR (1) BRPI0811112A2 (en)
CA (1) CA2683554A1 (en)
CL (1) CL2008001269A1 (en)
IL (1) IL201318A0 (en)
MA (1) MA31356B1 (en)
MX (1) MX2009011692A (en)
RU (1) RU2009144842A (en)
TN (1) TN2009000427A1 (en)
TW (1) TW200908964A (en)
WO (1) WO2008137630A1 (en)
ZA (1) ZA200906739B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (en) * 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
MXPA06004735A (en) * 2003-10-27 2006-12-14 S Bio Pte Ltd Acylurea connected and sulfonylurea connected hydroxamates.
WO2006075165A1 (en) * 2005-01-13 2006-07-20 Btg International Limited Combination of oncolytic viruses with angiogenesis inhibitors

Also Published As

Publication number Publication date
WO2008137630A1 (en) 2008-11-13
AU2008247603A1 (en) 2008-11-13
RU2009144842A (en) 2011-06-10
JP2010526149A (en) 2010-07-29
IL201318A0 (en) 2010-05-31
EP2142190A1 (en) 2010-01-13
BRPI0811112A2 (en) 2014-12-23
MX2009011692A (en) 2009-11-10
TW200908964A (en) 2009-03-01
KR20100016171A (en) 2010-02-12
TN2009000427A1 (en) 2011-03-31
MA31356B1 (en) 2010-05-03
CN101674825A (en) 2010-03-17
CA2683554A1 (en) 2008-11-13
CL2008001269A1 (en) 2008-12-19

Similar Documents

Publication Publication Date Title
HK1256861A1 (en) Compositions for the treatment of gastrointestinal inflammation
IL248204A0 (en) Combination treatment of cd38-expressing tumors
HK1208237A1 (en) Methods for the treatment of gout
EP2200439A4 (en) Hdac inhibitors
PL2303021T3 (en) Compounds for the treatment of cancer
EP2049139A4 (en) Treatment of ras-expressing tumors
PL2040753T3 (en) Progastrin inhibitors in the treatment of colon cancer
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
HRP20130395T1 (en) Treatment of melanoma
EP2328604A4 (en) The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2352501A4 (en) Compounds for the treatment of osteoporosis and cancers
PL2263751T3 (en) Isoxazole compound for the treatment of gastrointestinal cancers
GB0723100D0 (en) Treatment of HFnEF
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
IL201318A0 (en) Use of hdac inhibitors for the treatment of gastrointestinal cancers
GB0602857D0 (en) The treatment of sialorrhoea
ZA200906906B (en) Use of HDAC inhibitors for the treatment of melanoma
IL201439A0 (en) Use of hdac inhibitors for the treatment of melanoma
PL2214677T3 (en) Compositions for the treatment of inflammation of the gastrointestinal tract
GB0604114D0 (en) Combinations for the treatment of cancer
GB0712513D0 (en) Treatment of cancer
GB0602855D0 (en) The Treatment Of Sialorrhoea